Diagnosis and differentiation of htlv-i and htlv-ii infection by enzyme immunoassays using synthetic peptides

Research output: Contribution to journalArticle

Abstract

Summary: Synthetic peptides from the major envelope protein of HTLV-I (ENV-I, amino acid 177–213) and HTLV-II (ENV-II, amino acid 173–209) and a conserved region of the transmembrane protein (TM, amino acid 378–402) were used as antigens in microtiter plate enzyme immunoassays (EIA) to detect and discriminate antibodies to HTLV-I and II. The ENV-I and ENV-II peptide EIAs were able to correctly discriminate HTLV-I and II infections in 17 of 18 subjects whose infections were determined by a gene amplification method. Sera from 100 of 107 subjects with serologically confirmed infection with HTLV-I/II and 0 of 218 seronegative controls reacted with one or more of the peptides (sensitivity, 93.5%; specificity, 100%). Ninety-six of the 100 peptide positive sera reacted exclusively with either the ENV-I or the ENV-II peptide, thereby differentiating the two viral infections. The pattern of reactivity to the ENV peptides was distinct in different populations. Patients attending an Emergency Department, who had a history of drug abuse, and male inmate entering a correctional facility only had antibody reactivity to the ENV-II peptide. Subjects from Haiti and patients with HTLV-associated neurological disease only had antibody reactivity to the ENV-I peptide. Peptide-based enzyme immunoassays that distinguish antibodies to HTLV-I and HTLV-II will facilitate studies of the epidemiology of HTLV.

Original languageEnglish (US)
Pages (from-to)1190-1197
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume4
Issue number12
StatePublished - 1991

Fingerprint

Immunoenzyme Techniques
Peptides
Infection
Human T-lymphotropic virus 2
HTLV-I Antibodies
Amino Acids
HTLV-II Antibodies
HTLV-II Infections
HTLV-I Infections
Haiti
Human T-lymphotropic virus 1
Antibodies
Gene Amplification
Virus Diseases
Serum
Substance-Related Disorders
Hospital Emergency Service
Epidemiology
Proteins
Antigens

Keywords

  • Envelope proteins
  • Enzyme immunoassay
  • HTLV-I
  • HTLV-II
  • Synthetic peptides

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Virology
  • Immunology and Allergy

Cite this

@article{4e9d0ffd35f74f6cb62fbf0a0d43af19,
title = "Diagnosis and differentiation of htlv-i and htlv-ii infection by enzyme immunoassays using synthetic peptides",
abstract = "Summary: Synthetic peptides from the major envelope protein of HTLV-I (ENV-I, amino acid 177–213) and HTLV-II (ENV-II, amino acid 173–209) and a conserved region of the transmembrane protein (TM, amino acid 378–402) were used as antigens in microtiter plate enzyme immunoassays (EIA) to detect and discriminate antibodies to HTLV-I and II. The ENV-I and ENV-II peptide EIAs were able to correctly discriminate HTLV-I and II infections in 17 of 18 subjects whose infections were determined by a gene amplification method. Sera from 100 of 107 subjects with serologically confirmed infection with HTLV-I/II and 0 of 218 seronegative controls reacted with one or more of the peptides (sensitivity, 93.5{\%}; specificity, 100{\%}). Ninety-six of the 100 peptide positive sera reacted exclusively with either the ENV-I or the ENV-II peptide, thereby differentiating the two viral infections. The pattern of reactivity to the ENV peptides was distinct in different populations. Patients attending an Emergency Department, who had a history of drug abuse, and male inmate entering a correctional facility only had antibody reactivity to the ENV-II peptide. Subjects from Haiti and patients with HTLV-associated neurological disease only had antibody reactivity to the ENV-I peptide. Peptide-based enzyme immunoassays that distinguish antibodies to HTLV-I and HTLV-II will facilitate studies of the epidemiology of HTLV.",
keywords = "Envelope proteins, Enzyme immunoassay, HTLV-I, HTLV-II, Synthetic peptides",
author = "Viscidi, {Raphael P} and Peter Hill and Shuojia Li and Cerny, {Erich H.} and David Vlahov and Homayoon Farzadegan and Halsey, {Neal A} and Kelen, {Gabor D} and Quinn, {Thomas C}",
year = "1991",
language = "English (US)",
volume = "4",
pages = "1190--1197",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Diagnosis and differentiation of htlv-i and htlv-ii infection by enzyme immunoassays using synthetic peptides

AU - Viscidi, Raphael P

AU - Hill, Peter

AU - Li, Shuojia

AU - Cerny, Erich H.

AU - Vlahov, David

AU - Farzadegan, Homayoon

AU - Halsey, Neal A

AU - Kelen, Gabor D

AU - Quinn, Thomas C

PY - 1991

Y1 - 1991

N2 - Summary: Synthetic peptides from the major envelope protein of HTLV-I (ENV-I, amino acid 177–213) and HTLV-II (ENV-II, amino acid 173–209) and a conserved region of the transmembrane protein (TM, amino acid 378–402) were used as antigens in microtiter plate enzyme immunoassays (EIA) to detect and discriminate antibodies to HTLV-I and II. The ENV-I and ENV-II peptide EIAs were able to correctly discriminate HTLV-I and II infections in 17 of 18 subjects whose infections were determined by a gene amplification method. Sera from 100 of 107 subjects with serologically confirmed infection with HTLV-I/II and 0 of 218 seronegative controls reacted with one or more of the peptides (sensitivity, 93.5%; specificity, 100%). Ninety-six of the 100 peptide positive sera reacted exclusively with either the ENV-I or the ENV-II peptide, thereby differentiating the two viral infections. The pattern of reactivity to the ENV peptides was distinct in different populations. Patients attending an Emergency Department, who had a history of drug abuse, and male inmate entering a correctional facility only had antibody reactivity to the ENV-II peptide. Subjects from Haiti and patients with HTLV-associated neurological disease only had antibody reactivity to the ENV-I peptide. Peptide-based enzyme immunoassays that distinguish antibodies to HTLV-I and HTLV-II will facilitate studies of the epidemiology of HTLV.

AB - Summary: Synthetic peptides from the major envelope protein of HTLV-I (ENV-I, amino acid 177–213) and HTLV-II (ENV-II, amino acid 173–209) and a conserved region of the transmembrane protein (TM, amino acid 378–402) were used as antigens in microtiter plate enzyme immunoassays (EIA) to detect and discriminate antibodies to HTLV-I and II. The ENV-I and ENV-II peptide EIAs were able to correctly discriminate HTLV-I and II infections in 17 of 18 subjects whose infections were determined by a gene amplification method. Sera from 100 of 107 subjects with serologically confirmed infection with HTLV-I/II and 0 of 218 seronegative controls reacted with one or more of the peptides (sensitivity, 93.5%; specificity, 100%). Ninety-six of the 100 peptide positive sera reacted exclusively with either the ENV-I or the ENV-II peptide, thereby differentiating the two viral infections. The pattern of reactivity to the ENV peptides was distinct in different populations. Patients attending an Emergency Department, who had a history of drug abuse, and male inmate entering a correctional facility only had antibody reactivity to the ENV-II peptide. Subjects from Haiti and patients with HTLV-associated neurological disease only had antibody reactivity to the ENV-I peptide. Peptide-based enzyme immunoassays that distinguish antibodies to HTLV-I and HTLV-II will facilitate studies of the epidemiology of HTLV.

KW - Envelope proteins

KW - Enzyme immunoassay

KW - HTLV-I

KW - HTLV-II

KW - Synthetic peptides

UR - http://www.scopus.com/inward/record.url?scp=0025720722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025720722&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 1190

EP - 1197

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 12

ER -